Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desmopressin for Reversal of Antiplatelet Drugs in Stroke Due to Haemorrhage (DASH)
NCT03696121Phase 2Completed
- Sponsor
- University of Nottingham
- Start
- Apr 2019
- Primary completion
- Jun 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of desmopressin in intracerebral hemorrhage (ICH) (2 arms), sponsored by University of Nottingham. Primary endpoints: Number of eligible patients who received allocated treatment at 90 days, Rate of eligible patients randomised at 18 months and 5 more. Started Apr 2019; status: completed.
02
Drugs
desmopressin
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT03696121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03696121.